CbdMD, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025
Published on 05/15/2025 at 16:07
Share
cbdMD, Inc. reported earnings results for the second quarter and six months ended March 31, 2025. For the second quarter, the company reported sales was USD 4.75 million compared to USD 4.82 million a year ago. Revenue was USD 4.75 million compared to USD 4.38 million a year ago. Net loss was USD 0.480757 million compared to USD 3.01 million a year ago. Basic loss per share from continuing operations was USD 1.9 compared to USD 10.84 a year ago.
For the six months, sales was USD 9.86 million compared to USD 10.19 million a year ago. Revenue was USD 9.86 million compared to USD 9.75 million a year ago. Net loss was USD 0.465662 million compared to USD 4.01 million a year ago. Basic loss per share from continuing operations was USD 3.67 compared to USD 16.23 a year ago.
cbdMD, Inc. is a cannabidiol (CBD) company. The Company has a comprehensive line of United States produced, THC-free CBD products, including NSF Certified for Sport products, as well as its new Full Spectrum products. The Company's flagship brands include cbdMD and Paw CBD, as well as its functional mushroom brand ATRx Labs. Its cbdMD brand includes high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD sleep aids and CBD drink products including its Herbal Oasis Social Tonic and an array of Farm Act compliant Delta 9 products. Its Paw CBD brand of pet products includes veterinarian-formulated products including tinctures, chews, topicals products in varying strengths, and its ATRx brand of natural functional mushroom support. Its cbdMD, Paw CBD and ATRx products are distributed through its e-commerce websites, third party e-commerce sites, select distributors and marketing partners as well as a variety of brick-and-mortar retailers.
